BlackRock Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$100M Sell
2,761,360
-73,804
-3% -$2.95M 0.12% 170
2016
Q3
$130M Sell
2,835,164
-638,394
-18% -$33.3M 0.16% 135
2016
Q2
$174M Sell
3,473,558
-18,029
-0.5% -$960K 0.22% 98
2016
Q1
$187M Sell
3,491,587
-219,368
-6% -$12.9M 0.24% 87
2015
Q4
$244M Buy
3,710,955
+116,913
+3% +$7.22M 0.31% 71
2015
Q3
$203M Sell
3,594,042
-846,614
-19% -$54.9M 0.27% 83
2015
Q2
$262M Buy
4,440,656
+45,321
+1% +$2.8M 0.33% 64
2015
Q1
$274M Buy
4,395,335
+1,276,153
+41% +$74.2M 0.36% 59
2014
Q4
$179M Buy
3,119,182
+474,886
+18% +$26.5M 0.24% 93
2014
Q3
$142M Buy
2,644,296
+1,114,323
+73% +$59M 0.2% 114
2014
Q2
$80.2M Buy
1,529,973
+315,228
+26% +$16.1M 0.11% 189
2014
Q1
$64.2M Buy
1,214,745
+530,747
+78% +$24.5M 0.09% 207
2013
Q4
$27.4M Buy
683,998
+246,398
+56% +$9.7M 0.04% 393
2013
Q3
$16.5M Buy
437,600
+67,386
+18% +$2.63M 0.03% 545
2013
Q2
$14.5M Buy
+370,214
New +$14.4M 0.03% 551

Other funds holding TEVA

BlackRock Investment Management's TEVA Position: Q4 2016 in Review

BlackRock Investment Management reduced its Teva Pharmaceuticals (TEVA) stake by 2.6% in Q4 2016, selling an estimated $2.95M and leaving 2,761,360 shares worth $100M. The position accounts for 0.12% of the portfolio, ranked #170.

BlackRock Investment Management first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $274M in Q1 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • BlackRock Investment Management held 2,761,360 shares of Teva Pharmaceuticals worth $100M as of Q4 2016.
  • BlackRock Investment Management sold 73,804 Teva Pharmaceuticals shares in Q4 2016, an estimated $2.95M.
  • Teva Pharmaceuticals made up 0.12% of BlackRock Investment Management's portfolio in Q4 2016, its #170 holding.
  • BlackRock Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Teva Pharmaceuticals position peaked at $274M in Q1 2015.
  • 738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.